Skip to main content
SpringerLink
Log in

Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer

A multi-institutional cooperative study

  • Published:
Biotherapy

Abstract

Forty-three patients with malignant pleurisy due to lung cancer were entered into the trial to evaluate clinical efficacy of intrapleural instillation of recombinant interleukin-2 (RIL-2). Among 35 evaluable patients, serial cytological examinations of pleural effusion following the start of the treatment revealed disappearance of malignant cells in 26 (74%). Malignant cells were detected again in 7 of the 26, however, cytology remained negative in the other 19 patients for longer than 4 weeks. Pleural effusion disappeared roentogenographically in 13 of 35 evaluable patients. Additional 8 patients demonstrated marked decrease of pleural effusion. Complete response (CR) which means disappearance of both malignant cells and pleural effusion for longer than 4 weeks was obtained in 13 of the 35 patients (37%). No serious side effects were experienced in this trial. These results indicate that intrapleural RIL-2 is one of candidates to control intractable malignant pleurisy due to lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson CG, Reichert CM. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.

    PubMed  Google Scholar 

  2. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG,White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889–905.

    PubMed  Google Scholar 

  3. Rosenberg SA, Lotze ML, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surgery 1989; 210: 474–85.

    Google Scholar 

  4. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Okdham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905.

    PubMed  Google Scholar 

  5. Donohue JH, Rosenberg SA. The fate of interleukin-2 afterin vivo administration. J Immunol 1983; 130: 2203–8.

    PubMed  Google Scholar 

  6. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R, Hersey P. Clearance rates and systemic effects of intravenously administrated interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 1983; 47: 123–33.

    PubMed  Google Scholar 

  7. Hang AE, Hyatt CL, Rosenberg SA. Systemic administration of recombinant human interleukin-2 in mice. J Biol Response Modifiers 1984; 3: 561–72.

    Google Scholar 

  8. Yasumoto K, Miyazaki K, Nagashima A, Ishida T, Kuda T, Yano T, Sugimachi K, Nomoto K. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res. 1987; 47: 2184–7.

    PubMed  Google Scholar 

  9. Morgan DA, Ruscetti FW, Gallo R. Selectivein vitro growth of T lymphocytes from normal human bone marrows. Science (Wash DC) 1976; 193: 1007–8.

    Google Scholar 

  10. Baker PE, Gillis S, Ferm MM, Smith KA. The effect of T cell growth factor on the generation of cytolytic T cells. J Immunol 1982; 121: 2168–73.

    Google Scholar 

  11. Henney CS, Kuribayashi K, Kern DE, Gills S. Interleukin-2 augment natural killer cell activity. Nature (Lond.) 1981; 291: 335–8.

    Google Scholar 

  12. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41: 4420–5.

    PubMed  Google Scholar 

  13. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Respiratory Disease Center, Matsuyama Red Cross Hospital, Bunkyo-cho 1, 790, Matsuyama

    Kosei Yasumoto

  2. Third Department of Internal Medicine, School of Medicine, Tokushima University, Kuramoto-cho 3-18-15, 770, Tokushima, Japan

    Takeshi Ogura

Authors
  1. Kosei Yasumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yasumoto, K., Ogura, T. Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Biotherapy 3, 345–349 (1991). https://doi.org/10.1007/BF02221327

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02221327

Key words

Search

Navigation